<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837978</url>
  </required_header>
  <id_info>
    <org_study_id>Tacrolimus RA QiluH</org_study_id>
    <nct_id>NCT02837978</nct_id>
  </id_info>
  <brief_title>The Clinical Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment</brief_title>
  <official_title>Prospective Clinical Study to Observe the Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qiang Shu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to observed prospectively the efficacy and safety of 6 months
      treatment of Tacrolimus alone or with methotrexate (MTX) in moderate and severe Chinese RA
      patients who shown insufficiency response or intolerance to DMARDs
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll 100 cases of refractory rheumatoid arthritis (RA) patients in
      Chinese，who are in moderate or severe disease activity and insufficiency response or
      intolerance to DMARDs. The participants plan to be treated with Tacrolimus alone, or along
      with methotrexate (MTX) if participants were tolerant to MTX. The efficacy and safety of 6
      month Tacrolimus treatment in RA patients will be evaluated with DAS28 and other disease
      activity indices.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Disease Activity Score 28 (DAS28) at 24 weeks</measure>
    <time_frame>Baseline, 12 weeks, 24weeks</time_frame>
    <description>Change from baseline Disease Activity Score 28 (DAS28) at 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline ACR20 response rate at 24 weeks</measure>
    <time_frame>Baseline, 12 weeks, 24weeks</time_frame>
    <description>Change from baseline ACR20 response rate at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Clinical disease activity index (CDAI) at 24 weeks</measure>
    <time_frame>Baseline, 12 weeks, 24weeks</time_frame>
    <description>Change from baseline Clinical disease activity index (CDAI) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Simplified Disease Activity Index (SDAI) at 24 weeks</measure>
    <time_frame>Baseline, 12 weeks, 24weeks</time_frame>
    <description>Change from baseline Simplified Disease Activity Index (SDAI) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Erythrocyte Sedimentation Rate (ESR) at 24 weeks</measure>
    <time_frame>Baseline, 12 weeks, 24weeks</time_frame>
    <description>Change from baseline Erythrocyte Sedimentation Rate (ESR) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline C-Reactive Protein (CRP) at 24 weeks</measure>
    <time_frame>Baseline, 12 weeks, 24weeks</time_frame>
    <description>Change from baseline C-Reactive Protein (CRP) at 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline swollen joint number (SW28) at 24 weeks</measure>
    <time_frame>Baseline, 12 weeks, 24weeks</time_frame>
    <description>Change from baseline swollen joint number (SW28) at 24 weeks. SW28 means the number of joints with swelling counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline tenderness joint number (T28) at 24 weeks.</measure>
    <time_frame>Baseline, 12 weeks, 24weeks</time_frame>
    <description>Change from baseline tenderness joint number (T28) at 24 weeks. T28 means the number of joints with tenderness upon touching counted in 28 synovial joints, including proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2) bilateral.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Health Assessment Questionnaire (HAQ) at 24 weeks</measure>
    <time_frame>Baseline, 12 weeks, 24weeks</time_frame>
    <description>Change from baseline Health Assessment Questionnaire (HAQ) at 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RA patients treated with tacrolimus, without MTX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus + MTX group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RA patients treated with tacrolimus and MTX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid) until the endpoint or unacceptable toxicity develops.</description>
    <arm_group_label>Tacrolimus group</arm_group_label>
    <arm_group_label>Tacrolimus + MTX group</arm_group_label>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>MTX： 7.5mg to 15mg, po, once per week (Qw) until the endpoint or unacceptable toxicity develops.</description>
    <arm_group_label>Tacrolimus + MTX group</arm_group_label>
    <other_name>methotrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed based on 1987 ACR classification criteria for rheumatoid arthritis

          2. Age ≥18 years;

          3. Medium or high disease activity (DAS28≥3.2);

          4. Extra-articular manifestations (such as pulmonary fibrosis, proteinuria, leukopenia
             and peripheral neuropathy ) of RA patients are stable or no significant progress;

          5. Patients have not been treated with any biologic drugs;

          6. Patients have a history of baseline medication with methotrexate (MTX) or other DMARDs
             drugs (leflunomide, hydroxychloroquine, iguratimod, sulfasalazine, tripterygium
             Glycosides) for 3 months, but couldn't achieve clinical remission or low disease
             activity; or couldn't tolerate one or more DMARDs, and DAS28≥3.2;

          7. Dose of prednisone and NSAIDs remain stable for at least one month.

        Exclusion Criteria:

          1. Patients with acute or chronic infections such as active bacterial, viral, fungal,
             tuberculosis infection or active hepatitis B;

          2. Platelet counts(PLT) &lt;80 x 10^9 / L, or white blood cell (WBC) &lt;3 x 10^9 / L;

          3. Propionate acid aminotransferase (ALT) or aspartate aminotransferase (AST) is two
             times higher than the upper limit of normal;

          4. Renal insufficiency: serum Cr ≥ 176 umol / L;

          5. Pregnant or nursing women (breastfeeding) ；

          6. Patients has a history of malignancy (cure time in less than 5 years);

          7. Patients with severe or poorly controlled hypertension, diabetes or cardiac
             dysfunction;

          8. Other comorbidities that cannot be treated with immune suppressants. In addition, once
             patients experience severe adverse drug reactions、ineffective treatment or rapid
             progression of rheumatoid arthritis, then quit this research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Shu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Shu, Dr.</last_name>
    <phone>0086-0531-82169654</phone>
    <email>shuqiang@sdu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yameng Sui</last_name>
    <phone>0086-0531-82169654</phone>
    <email>qlshuqiang@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qilu Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Lv, Prof.</last_name>
      <phone>0086-0531-82169166</phone>
      <email>qlyykyc@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Qiang Shu</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Arthritis, Rheumatoid</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Treatment outcome</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available within 12 months of study completion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

